A5016770705- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Organ Transplantation Techniques and Outcomes
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Cancer, Hypoxia, and Metabolism
- Economic and Financial Impacts of Cancer
- Hepatitis C virus research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver physiology and pathology
- Drug-Induced Hepatotoxicity and Protection
- Cancer Genomics and Diagnostics
- Liver Diseases and Immunity
- Ultrasound and Hyperthermia Applications
- Hepatitis B Virus Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Nutrition and Health in Aging
- Gastroesophageal reflux and treatments
- Immune cells in cancer
- Multiple Sclerosis Research Studies
Kansai Medical University
2025
Chiba University
2013-2024
Chiba University Hospital
2023
University College London
2015-2022
The Royal Free Hospital
2020
Hospital Clínic de Barcelona
2015
Ocera Therapeutics (United States)
2015
Grifols (United States)
2015
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015
Martin Luther University Halle-Wittenberg
2015
The present study aimed to assess the efficacy and safety of lenvatinib verify possibility for expanded indication from REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) real-world practice, primarily focusing on population that was excluded trial.We retrospectively collected data HCC who were administered 7 institutions Japan.Of 152 patients, 95 57 received first-line second- or later-line systemic therapies, respectively. median progression-free survival Child-Pugh...
Programmed death-ligand 1 (PD-L1) plays an essential role in tumor cell escape from anti-tumor immunity various types of cancer, including gastric cancer (GC). The present study investigated the intracellular and membrane-bound expression PD-L1 GC lines MKN1, MKN74, KATO III OCUM-1. Furthermore, soluble (sPD-L1) level supernatant cells serum patients with healthy controls was determined by ELISA. Interferon (IFN)-γ treatment resulted increased cytoplasmic a dose-dependent manner, except for...
The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact availability sequential MTAs has not been fully verified yet.We retrospectively collected data on whole clinical course 877 who received any first-line systemic therapy for HCC between June 2009 and March 2019. study population was divided into 3 groups according date MTA administration (period 1: 2009-2012, n = 267;...
There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration after and explore candidates second-line agents the failed therapy.We retrospectively collected data on HCC who received as first-line agent 7 institutions.Overall survival progression-free (PFS) 178 were 13.3 months (95% confidence interval [CI], 11.5-15.2) 6.7 CI, 5.6-7.8), respectively. Sixty-nine 151 (45.7%)...
Abstract Acute-on-chronic liver failure (ACLF) is characterized predominantly by non-apoptotic forms of hepatocyte cell death. Necroptosis a form programmed lytic death in which receptor interacting protein kinase (RIPK) 1, RIPK3 and phosphorylated mixed lineage domain-like (pMLKL) are key components. This study was performed to determine the role RIPK1 mediated ACLF. plasma levels hepatic expression RIPK1, RIPK3, pMLKL were measured healthy volunteers, stable patients with cirrhosis,...
Abstract Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from REFLECT trial, a phase III trial that compared with sorafenib. Patients Methods: multicenter, nonrandomized, open-label prospective was conducted at 10 medical facilities Japan (jRCTs031190017). Eligible had advanced hepatocellular carcinoma (HCC) were suitable for therapy. The included high tumor burden (with >50% intrahepatic volume, main...
Abstract FGF19/FGFR4 autocrine signaling is one of the main targets for multi-kinase inhibitors (MKIs). However, molecular mechanisms underlying in antitumor effects to MKIs hepatocellular carcinoma (HCC) remain unclear. In this study, impact FGFR4/ERK inhibition on HCC following MKI treatment was analyzed vitro and vivo assays. Serum FGF19 patients treated using MKIs, such as sorafenib (n = 173) lenvatinib 40), measured by enzyme-linked immunosorbent assay. Lenvatinib strongly inhibited...
The aim was to examine the effect of free fatty acids on regulation PPARγ-PGC1α pathway, and PPARγ/PGC1α in NAFLD.The mRNA protein expression PGC1α phospho/total PPARγ were examined Huh7 cells after palmitate/oleate treatment with/without transfection with siRNA against PGC1a.The palmitate content, liver control NAFLD mice.Palmitate (500 μM), but not oleate, increased phospho (PGC1α, 1.42-fold, P=0.038; PPARγ, 1.56-fold, P=0.022).The palmitate-induced reduced (0.46-fold), expressions...
To elucidate the natural history and longitudinal outcomes in cirrhotic patients with non-forward portal flow (NFPF).The present retrospective study consisted of 222 (120 males 102 females; age, 61.7 ± 11.1 years). The hemodynamics were evaluated at baseline during observation period using both pulsed color Doppler ultrasonography. diameter (mm), direction, mean velocity (cm/s), volume (mL/min) assessed trunk, splenic vein, superior mesenteric collateral vessels. average values from 2 to 4...
Significance of portal hemodynamics for non-invasive marker cirrhosis remains unclear. The aim was to determine the value on Doppler ultrasound predicting decompensation and prognosis in cirrhosis.This retrospective study comprised 236 cirrhotic patients (132 males, 104 females; age 63.7 ± 11.3 years; 110 compensated, 126 decompensated). Clinical data, including findings, were analyzed with respect prognosis. median follow-up period 33.2 months (0.1-95.4).Fifty-three developed clinical...
Abstract Background During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with incidence and exacerbation PH-related complications, including usefulness contrast-enhanced computed tomography (CECT) in during therapy. Methods A total 669 patients who received therapy as first-line treatment (443 for sorafenib, 131 lenvatinib, 90 atezolizumab/bevacizumab [ATZ/BEV]) were enrolled this retrospective...
Hepatocellular carcinoma (HCC) is typically accompanied by abundant arterial blood flow.Although angiogenic growth factors such as Angiopoietin 2 (Ang2) play a central role in tumor angiogenesis HCC, the of serum Ang2 biomarker HCC remains unclear.In this study, we aimed to investigate potential diagnostic and prognostic using sandwich enzyme-linked immunosorbent assay (ELISA).The median levels controls (n=20), chronic liver disease patients (n=98), (n=275) were 1.58, 2.33, 3.53 ng/mL,...
Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought major paradigm shift in the unresectable hepatocellular carcinoma (HCC). Gain-of-function mutation CTNNB1 contributes to resistance ICI monotherapy through framework non-T-cell-inflamed tumor microenvironment. However, whether renders ATZ/BV similar remains be elucidated. In this study,...
Abstract Background Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long‐term and association with adverse events real‐world practice are unknown. This study was designed to shed light on these issues. Methods In this multicenter retrospective study, data were collected from patients advanced hepatocellular carcinoma treated plus bevacizumab seven institutions Japan. The authors focused related vascular endothelial growth factor (VEGF)...
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated immune checkpoint inhibitors (ICI). The aim of this study clarify the reality HPD advanced hepatocellular carcinoma (HCC) who were atezolizumab plus bevacizumab (Atez/Bev) using dynamics. Methods Medical records consecutive HCC Atez/Bev retrospectively reviewed. was defined as more than two- or fourfold increase...
Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing hypertension. However, characteristics outcomes of IPH with ascites have not yet been determined. The aim the study was to examine influence on long-term clinical course IPH. This observational compared findings including hemodynamics demonstrated by Doppler ultrasonography between 166 cirrhosis (87 males 79 females; mean age ± standard deviation, 62.5 11.8 years; range, 20–89 years) 14 patients (3 11 64.2 6.6...
<b><i>Background:</i></b> Intermediate-stage hepatocellular carcinoma (HCC) has a high frequency of recurrence and progression to advanced stage after transarterial chemoembolization (TACE), particularly in patients with tumor burden. Promising new results from immune checkpoint inhibitors (ICIs) ICI-based therapies are expected replace TACE, especially HCC <b><i>Aims:</i></b> The present study aimed evaluate the effectiveness TACE view design...
Organ failure in patients with acute decompensation (AD) is a defining characteristic of acute-on-chronic liver (ACLF). However, the clinical features AD during long-term course hepatocellular carcinoma (HCC) are still poorly understood. This study aimed to clarify and impact AD/ACLF on prognosis after treatment for HCC.This retrospective enrolled 556 consecutive who were initially diagnosed HCC, analyses conducted taking into account HCC type, stage, presence or absence cirrhosis.During...